Earlier this month, Raptor Pharmaceutical Corp.'s RP103 (cysteamine bitartrate delayed-release) failed a phase IIb trial in pediatric nonalcoholic steatohepatitis (NASH), but the letdown hasn't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback